united therapeutics glp-1 receptor agonist agonists Biased agonism and polymorphic variation

GLP-1 lawsuits primarily target pharmaceutical manufacturers that developed and marketed semaglutide and tirzepatide medications used for diabetes treatment and weight loss

Sodium-Glucose Co-Transporter 2 Inhibition with Empagliflozin Improves Cardiac Function After Cardiac Arrest in Rats by Enhancing Mitochondrial Energy Metabolism

Embracing the pros and cons of the new weight loss medications (semaglutide, tirzepatide, etc.)

As a result, the increased secondary BAs can activate TGR5, which increases L-cells and GLP-1 secretion by inhibiting the RhoA/ROCK pathway and inducing YAP activation [157, 203]

98 Although located in the sinoatrial node, GLP-1 RAs influence the cardiovascular system through several other mechanisms, including the use of myocardial glucose, improvement of left ventricular function, myocardial ischaemic protection, increased heart rate, vasodilation, anti-atherosclerotic effects, and blood pressure reduction

Oxidative stress also seems to be an important pathophysiological mechanism of NAFLD (190)